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Alterations in xenobiotic metabolizing enzyme
(XME) expression across the life course, along
with genetic, nutritional, and environmental reg-
ulation, can influence how organisms respond
to toxic insults. In this study, we investigated
the hypothesis that in utero exposure to the
endocrine active compound, bisphenol A (BPA),
influences expression and epigenetic regulation
of phase I and II XME genes during develop-
ment. Using healthy 1st to 2nd trimester human
fetal liver specimens quantified for internal BPA
levels, we examined XME gene expression
using PCR Array (n58) and RNA-sequencing
(n512) platforms. Of the greater than 160
XME genes assayed, 2 phase I and 12 phase
II genes exhibited significantly reduced expres-
sion with higher BPA levels, including isoforms
from the carboxylesterase, catechol O-methyl-
transferase, glutathione S-transferase, sulfotrans-
ferase, and UDP-glucuronosyltransferase families.
When the promoters of these candidate genes
were evaluated in silico, putative binding sites
for the E-twenty-six (ETS) and activator protein1
(AP1) related transcription factor families were
identified and unique to 97% of all candidate
transcripts. Interestingly, many ETS binding sites
contain cytosine-guanine dinucleotides (CpGs)
within their consensus sequences. Thus, quantita-
tive analysis of CpG methylation of three candi-
date genes was conducted across n550
samples. Higher BPA levels were associated
with increased site-specific methylation at
COMT (P<0.005) and increased average
methylation at SULT2A1 (P<0.020) promoters.
While toxicological studies have traditionally
focused on high-dose effects and hormonal
receptor mediated regulation, our findings sug-
gest the importance of low-dose effects and
nonclassical mechanisms of endocrine disruption
during development. Environ. Mol. Mutagen.
55:184–195, 2014. VC 2013 Wiley Periodicals, Inc.
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INTRODUCTION
A compound’s absorption, distribution, metabolism, and
excretion via biotransformation pathways dictate its thera-
peutic or toxic potential. Specifically, changes in xenobiotic
metabolizing enzyme (XME) gene expression and activity
can alter drug efficacy and toxicity, with the greatest dis-
crepancies observed in children compared with adults
[Alcorn and McNamara, 2003]. In general, the oxidizing
phase I XMEs functionalize compounds into active metabo-
lites while the conjugating phase II XMEs increase the
molecular weight of compounds for rapid excretion of toxic
metabolites [Caldwell et al., 1995]. Preliminary studies
indicate that relative XME expression and activity among
different classes and isoforms change drastically throughout
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the life course [Hines, 2008]. For example, the phase II
UDP-glucuronosyltransferase isoforms, UGT1A1 and
UGT1A6, are both expressed at low levels in the human
fetus; while UGT1A1 attains adult levels within months
after birth, the UGT1A6 isoform reaches adult levels at 10
years of age [McCarver and Hines, 2002]. Therefore, the
extent of metabolism of a xenobiotic chemical is dependent
on age and ontogeny, or the maturation of specific XMEs
[Allegaert et al., 2007]. Much of our understanding of
human XME ontogeny arises from adverse pharmaceutical
exposures or diseases throughout birth and infancy, or
extrapolations from rodent models [Saghir et al., 2012].
Comprehensive studies examining metabolism in early
human fetal development are limited; for example, recent
studies characterize only a handful of XMEs, such as ster-
oidogenic enzymes in 2nd trimester fetal liver [O’Shaugh-
nessy et al., 2013] or cytochrome p450s (CYP) and
glutathione s-transferases in fetal liver and adrenals [Wang
et al., 2008]. Evaluating ontogeny, especially throughout
human gestation, is thus of great importance in assessing
toxicity; however, obtaining suitable human specimens may
pose ethical and technical challenges.
In addition to drug metabolism, XMEs play an impor-
tant role in steroid homeostasis, neuroendocrine function,
and growth. Both endogenous and exogenous compounds
help regulate XME ontogeny and subsequently, metabolic
function. More recently, studies demonstrating the impor-
tance of hormonal regulation on the establishment of
hepatic metabolism throughout pregnancy and develop-
ment have emerged [Kennedy, 2008; Jeong, 2010]. Xeno-
biotics that can mimic endogenous hormones, such as
endocrine active compounds (EAC), can potentially mod-
ify baseline hormonal regulation of xenobiotic metabo-
lism and response to environmental stressors during
critical windows of development.
Bisphenol A (BPA), a synthetic estrogen used in the
production of polycarbonate plastics and epoxy resin, is a
controversial EAC that is of concern primarily in the
developing organism [Rubin, 2011]. Presence of BPA in
fetal tissue [Cao et al., 2012; Nahar et al., 2012], reduced
capacity for BPA metabolism in the fetus [Nahar et al.,
2012], and the ability for BPA transfer across the pla-
centa [Schonfelder et al., 2002; Balakrishnan et al., 2010;
Jimenez-Dıaz et al., 2010], place the developing human
fetus at a higher risk for BPA toxicity. Although the
human health consequences of BPA exposures are dis-
puted, several rodent studies suggest that developmental
exposure to BPA can alter susceptibility to disease later
in life by modifying the epigenome [Ho et al., 2006;
Bromer et al., 2010; Kundakovic and Champagne, 2011;
Anderson et al., 2012]. Thus, we hypothesize that BPA
dependent changes to epigenetic regulation of XME dur-
ing development may also result in latent effects on dis-
ease susceptibility. To date, research addressing BPAs
influence on XME expression and activity has been
limited to animal and in vitro models. For example, rat
hepatic microsome studies show that BPA inhibits CYP
enzymes, including activity for CYP1A2, CYP2C11, and
CYP2E1 [Hanioka et al., 2000; Pfeiffer and Metzler
2004]; yeast and human liver microsome studies associate
BPA with both competitive and noncompetitive inhibition
of UGT1A6 [Hanioka et al., 2008]; and human endome-
trial Ishikawa cell line studies show increased ALDH3A1
expression following BPA exposure [Naciff et al., 2010].
Interspecies differences in metabolism and/or relatively
high BPA exposure doses, however, limit the translation
of these findings for human risk assessment.
The influence of xenoestrogens on the maturation and
regulation of phase I and II xenobiotic metabolizing
enzymes has yet to be studied in humans. Here, utilizing
a comprehensive approach evaluating XME expression,
we identify multiple XME genes that are associated with
physiologically relevant concentrations of total BPA,
assess relative abundance of these XME mRNAs in the
developing human fetal liver, and investigate DNA meth-
ylation as a potential mechanism influencing biotransfor-
mation response to BPA exposure.
METHODS ANDMATERIALS
Tissue Samples
Human fetal liver samples were procured from the NIH-
funded University of Washington Birth Defects Research
Laboratory fetal biobank (2R24HD000836-47), and charac-
terized for BPA concentrations by the Kannan Laboratory
at the Wadsworth Center (New York State Department of
Health). As previously described [Nahar et al., 2012], fol-
lowing surgery and consent from volunteers undergoing
elective abortions during 1st and 2nd trimester of preg-
nancy (gestational day 74–120), healthy tissue specimens
were flash frozen and immediately stored in polycarbonate-
free tubing at 280C until processed for BPA analysis and
RNA/DNA extraction. No identifying clinical data were
available on samples except for sex and gestational age.
Total BPA concentrations measured in liver tissue ranged
from below the limit of quantification at 0.071 ng/g (LOQ/
2, where LOQ5 0.1 ng/g) up to 96.8 ng/g [Nahar et al.,
2012].
RNA Extraction and cDNA Synthesis
Total RNA was isolated from frozen liver tissue using
the AllPrep DNA/RNA/Protein kit (Qiagen, Valencia,
CA) according to the manufacturer’s instructions.
Approximately 10 to 20 mg of homogenized tissue was
added to 600 mL of Buffer RLT (containing 1% b-mer-
captoethanol) in a 2 mL round bottom polypropylene
eppendorf tube with a 5 mm stainless steel bead. Samples
were further homogenized in solution for 2 min at 20 Hz
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(23) in the TissueLyser II (Qiagen). The purity and quan-
tity of RNA was assessed using the Nanodrop 2000 spec-
trophotometer (Thermo Scientific, Wilmington, DE) and
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA). Only high quality samples with RNA integ-
rity number (RIN) >7 were used for RT2 Profiler PCR
Arrays (n5 8) and high-throughput RNA-sequencing
(n5 12). Three samples were run on both expression plat-
forms for a total sample size of n5 17.
To produce complementary DNA for each sample, 1
mg of total RNA template was used with the iScript
cDNA synthesis Kit (Bio-Rad, Hercules, CA) following
the manufacturer’s protocol. The thermocycler settings
for cDNA synthesis required incubation at 25C for 5
min, 42C for 60 min, and 90C for 5 min.
Human DrugMetabolism RT2 Pro¢lerTM PCR Array
Differential mRNA expression of various xenobiotic
metabolism genes were assessed by using two different
cataloged human arrays from SuperArray Biosciences
(Frederick, MD): the Phase I Enzyme PCR Array (PAH-
068E4) and the Phase II Enzyme PCR Array (PAH-
069E4). Each SYBR Green-based 96-well PCR Array
platform interrogates multiple genes and isoforms relevant
to a specific biological pathway along with five reference
genes and several controls per sample. Based on the dis-
tribution of total BPA levels measured in 50 fetal liver
samples [Nahar et al., 2012], the median BPA concentra-
tion (3.44 ng/g) was used as a cutoff for group categori-
zation. The final samples were chosen based on the
highest RIN scores and a >10-fold difference in average
total BPA between low and high exposure groups. Four
liver RNA samples exhibiting low total BPA concentra-
tions (1.2–2.9 ng/g) and four liver RNA samples exhibit-
ing high total BPA concentrations (35.4–56.1 ng/g) were
submitted to the University of Michigan Sequencing Core
facility and run on both PCR Array platforms using the
ABI Prism 7900 HT Sequence Detection System (Applied
Biosystems).
PCR Array Gene Expression Analysis
The threshold cycle (CT) was obtained for each target
gene, and an average reference CT was calculated for the
five endogenous reference genes: beta-2-microglobulin
(B2M), hypoxanthine phosphoribosyltransferase I (HPRT1),
ribosomal protein L13a (RPL13A), glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH), and beta actin (ACTb).
Positive PCR control and reverse transcription controls
were either undetected or had an extremely high CT value.
Results are reported as DCT, which represents the differ-
ence between the CT of the target gene versus the average
CT of the reference genes. The average DCT of the low
exposure samples were subtracted from the average DCT
of the high exposure samples to obtain the DDCT value,
and fold change was calculated as 22DDCT. A linear model
designed for microarray analysis was utilized to increase
the power to detect fold change differences in target arrays
by pooling information using the limma package of Bio-
conductor in R statistical software version 2.13.2 [Smyth,
2004]. Furthermore, P values were adjusted for multiple
comparisons using false discovery rate [Benjamini and
Hochberg, 1995]. Candidate genes were chosen based on
greater than 2-fold or less than 0.5-fold change and
P< 0.05.
Next Generation RNA Sequencing
To characterize the relative mRNA abundance of
XMEs in human fetal liver, regardless of sex or exposure,
we utilized information from a second set of samples
(n5 12, including three samples also used in the PCR
Arrays) submitted for high throughput next generation
mRNA sequencing (RNA-seq) using the Illumina HiSeq
2000 platform (Illumina, San Diego, CA). General work-
flow for next generation sequencing library construction
consisted of enrichment of poly-A RNA, fragmentation,
RNA clean up, cDNA synthesis using hexamer primers,
end repair, and adaptor ligation, as previously described
[Sengupta et al., 2011]. The raw sequencing image data
was analyzed with the Illumina analysis pipeline, using
single reads up to 150 base pairs (bp) in length. Over 438
million reads across 12 samples were obtained, with an
average read number of 36.5 million per sample. The
FastQC tool was used to perform quality control checks
on raw data. In order to utilize reads with the best quality
calls (FastQC per base sequence quality score above 28),
sequences were trimmed to 70 bases in length, and reads
were aligned to the hg19 human reference genome using
TopHat. Parameters with the best alignment and increased
search time were used in order to improve sensitivity.
After removing duplicate reads resulting from PCR dupli-
cates with SamTools, transcript abundance was measured
by CuffDiff v2.0.1 software as fragments per kilobase of
exon per million fragments mapped (FPKM). Total frag-
ment reads were tabulated and normalized across 12 sam-
ples. Approximately 152 genes of the phase I and phase
II genes on the PCR Arrays were identified in the RNA-
seq dataset along with their normalized FPKM reads. The
bottom and top quartile reads in FPKM are reported,
indicative of low and high relative expression of XME
genes within phase I and phase II pathways during
development.
Transcription Factor Binding Site Identification
An in silico bioinformatics approach was used to iden-
tify common promoter regulatory elements within PCR
Array BPA-associated candidate genes. Gene2Promoter
(Genomatix, Munich, Germany) software utilizes position
weight matrices to predict transcription factor binding
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sites (TFBS) 500 bp upstream and 100 bp downstream of
transcription start sites (TSS) of candidate genes [Carthar-
ius et al., 2005]. Using MatInspector, fasta-formatted
input sequences of the PCR Array candidate gene pro-
moters were compared, and common transcription factors
were clustered together into TFBS families or “matrix
families” based on similarities in binding domain or func-
tion. Regulatory families were reported when TFBS were
identified in >97% of all relevant transcripts of the candi-
date XME genes.
Bisulfite Conversion and Epityper Methylation Analysis
To quantitatively assess methylation, high quality DNA
using the Allprep kit was obtained from a larger clinical
cohort (total n5 50) including specimens tested for
expression on the PCR Array and RNA-seq platforms.
Approximately 1 mg of genomic DNA was subject to
sodium bisulfite treatment using the Qiagen Epitect kit
automated on the Qiagen Qiacube (Qiagen Inc., Valencia,
CA) in order to produce bisulfite converted DNA for
methylation analysis. Epitect methylated and unmethy-
lated human bisulfite converted samples (Qiagen) were
used as positive controls. T7 tagged primers for the mod-
erately expressed CES2, COMT, and SULT2A1 candidate
genes were designed for promoter methylation analysis
using the EpiDesigner Web tool (http://www.epidesigner.-
com/, Table IV). Candidate gene promoter regions con-
taining consensus sequences for ETS related transcription
factors were amplified using HotStarTaq master mix in a
30 mL PCR reaction. A standard HotStarTaq thermal
cycling setting was used for the three assays with the fol-
lowing changes: CES2 required annealing at 56C for 30
sec at 35 cycles, COMT required annealing at 60C for
30 sec at 35 cycles, and SULT2A1 required annealing at
56C for 30 sec at 40 cycles.
After in vitro transcription and uracil-cleavage of
amplicons as previously described [Coolen et al., 2007],
promoter methylation was quantified using the mass-
spectrometry based Sequenom MassArray EpiTYPER
platform (Sequenom, San Diego, CA) in the University of
Michigan DNA Sequencing Core. Associations between
amplicon average DNA methylation and total BPA expo-
sure were assessed using a linear mixed effects model.
For this model, percent methylation was the dependent
variable and CpG unit number was the random effect,
while total BPA exposure, sex, and gestational age were
set as fixed effects. The analysis incorporated multiple
site-specific CpG units (4 for CES2 and SULT2A1; 17 for
COMT) and accounted for correlations between adjacent
dinucleotides for each assay. The association between
CpG site-specific methylation of ETS consensus sequen-
ces and total BPA was assessed using multiple linear
regression after adjusting for sex and gestational age. For
each statistical analysis, regression diagnostics were used
to identify samples that deviate from standard linear
regression assumptions (e.g. constant variance and normal
distribution of residuals). Residuals were determined to
be within cook’s distance cutoff (<1); thus no data points
were excluded from the final analysis. Complete methyla-
tion data was analyzed for the following number of sam-
ples: n5 50 for CES2 and COMT, and n5 40 for
SULT2A1. Due to technical limitations, 10 samples failed
the SULT2A1 Sequenom assay, and SULT2A1 CpG site
#1, which falls within the ETS consensus sequence, was
not resolvable on any sample via the Sequenom platform.
RESULTS
BPA Exposure Dependent XME Gene Expression
Using the RT2 ProfilerTM PCR Array, we analyzed 167
genes involved in xenobiotic metabolism (93 phase I and
74 phase II enzyme isoforms) in human fetal liver speci-
mens. Using gene selection criteria (P< 0.05 and fold
change >2 or <0.5), 2 phase I genes and 12 phase II
genes exhibited altered expression based on low (1.2–2.9
ng/g total; n5 4) versus high (35.4–56.1 ng/g total;
n5 4) tissue BPA concentrations (Table I). All differen-
tially expressed candidate genes exhibited significantly
decreased expression in liver samples containing high
compared with low tissue BPA concentrations. The phase
I genes include the CES2 and CES5A carboxylesterase
isoforms, while the phase II genes include catechol-O-
methyltransferase (COMT), glutathione S-transferase
(GSTA5), sulfotransferase (SULT2A1, 1B1, 6B1, 1C3),
and UDP-glucuronosyltransferase (UGT1A3, 1A4, 1A6,
1A8, 1A9, 1A10).
Relative Expression Levels of XME Genes
RNA deep sequencing was employed to qualitatively
characterize the relative expression of 152 of the 167
phase I and phase II XME genes contained on the PCR
Arrays. While real-time polymerase chain reaction (RT-
qPCR) based techniques are the gold standard for quanti-
tative expression, RNA-seq platforms are important for
simultaneous characterization of hundreds or thousands of
genes; thus, this platform was utilized for exposure inde-
pendent comparative expression rather than identification
of differential expression. RNA-seq reads were reported
as fragments per kilobase of exon per million fragments
mapped (FPKM) using CuffDiff v2.0.1. Table II depicts
the bottom and top quartile FPKM reads separately for
phase I and phase II XME gene isoforms, with PCR
Array candidate XME genes depicted in red.
For phase I XME genes, the epoxide hydrolase, hydrox-
ysteroid dehydrogenase, and monoamine oxygenase gene
families were expressed at high levels while carboxylester-
ase and cyclooxygenase gene families were primarily
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expressed at low levels. In several instances, an isoform of
a gene family exhibited low expression while a second iso-
form of the same family exhibited high expression. For
example, while the alcohol dehydrogenase and aldehyde
dehydrogenase isoforms, ADH1A and ALDH1A1, were
both expressed at high levels, the ADH7 and ALDH3B2
isoforms were both expressed at low levels. Similarly, the
predominantly expressed cytochrome p450 and flavin
dependent monoxygenase isoforms were CYP3A7 and
FMO5, while the CYP11B2 and FMO2 isoforms were
expressed at low levels.
Among the phase II genes, guandinoacetate N-methyl-
transferase, histamine N-methyltransferase, and thiosulfate
sulfotransferase gene families were all expressed at high
levels, while arylalkalamine N-acetyltransferase, arylamine
N-acetyltransferase, and nicotinamide N-methyltransferase
TABLE II.Bottom and Top Quartile Expression (FPKM Reads from RNA-seq) of Phase I and Phase II XME Genes in Human
Fetal Liver Specimens (N5 12)
Biotransformation
pathway Gene family names Low expression (bottom 25%) High expression (top 25%)
Phase I Alcohol dehydrogenase ADH7 ADH1A, ADH6, ADH5
Aldehyde dehydrogenase ALDH3B2, ALD1A3 ALDH1A1, ALDH2, ALDH4A1
Carboxylesterase CES5A, CES3
Cytochrome P450 CYP4F8, CYP26C1, CYP11B2 CYP3A7, CYP27A1, CYP19A1
Epoxide hydrolase EPHX1, EPHX2
Flavin dependent monooxygenase FMO2 FMO5
Hydroxysteroid (17b) dehydrogenase HSD17B10
Monoamine oxygenase MAOB
Prostaglandin synthase/cyclooxygenase PTGS2, PTGES
Phase II Arylalkalamine N-acetyltransferase AANAT
Acyl-CoA synthetase ACSM1 ACSL4, ACSL1
Guanidinoacetate N-methyltransferase GAMT
Glutathione S-transferase GSTA5 GSTA1, GSTP1, GSTO1, MGST3, MGST1, MGST2
Histamine N-methyltransferase HNMT
Arylamine N-acetyltransferase NAT2
Nicotinamide N-methyltransferase NNMT
Sulfotransferase SULT6B1, SULT1B1, SULT1C3 SULT1A1
Thiosulfate sulfurtransferase TST
UDP-glucuronosyltransferase UGT2A1, UGT2B17, UGT1A1–10 UGT2B10, UGT2B4
Phase I XME genes with FPKM reads <0.1 and FPKM reads >9 represent the bottom and top quartile of XME expression. For phase II XME,
the genes at the bottom and top quartile of XME expression exhibit FPKM reads <0.2 and FPKM reads >12, respectively. Genes in bold are
BPA-associated candidate XMEs identified from PCR Arrays. While these genes show low expression, the remaining candidate genes (CES2,
COMT, and SULT2A1) show relatively moderate expression or FPKM reads.
TABLE I.Differentially Expressed Phase I and II XME Genes by High BPA Exposure
Xenobiotic
metabolism
enzyme Symbol Description Fold changea Adjusted P
Phase I CES2 Carboxylesterase 0.186 0.049
Phase I CES5A 0.124 0.049
Phase II COMT Catechol-O-methyltransferase 0.245 0.025
Phase II GSTA5 Glutathione S-transferase 0.140 0.049
Phase II SULT2A1 Sulfotransferase 0.248 0.025
Phase II SULT1B1 0.159 0.026
Phase II SULT6B1 0.054 0.026
Phase II SULT1C3 0.185 0.026
Phase II UGT1A3 UDP-glucuronosyltransferase 0.122 0.034
Phase II UGT1A4 0.121 0.028
Phase II UGT1A6 0.249 0.037
Phase II UGT1A8 0.048 0.025
Phase II UGT1A9 0.094 0.045
Phase II UGT1A10 0.187 0.026
Summary of XME genes identified as significantly altered in fetal liver with high BPA exposure compared with low BPA exposure using the human
xenobiotic metabolism Phase I and Phase II PCR Array platforms.
aFold change <0.5 is downregulation; fold change >2 is upregulation.
Environmental and Molecular Mutagenesis. DOI 10.1002/em
188 Nahar et al.
gene families were expressed at low levels. The more com-
mon conjugating families such as glutathione S-transferase,
sulfotransferase, and UDP-glucuronosyltransferase dis-
played isoforms that were variably expressed.
Interestingly, several BPA-associated candidate XME
genes identified through the PCR Arrays exhibited rela-
tively low expression in the 1st to 2nd trimester fetal
liver. They include CES5A, GSTA5, SULT6B1, SULT1B1,
SULT1C3, and the UGT1A related isoforms. While none
of the differentially expressed genes were expressed at
high levels in early development, CES2, COMT, and
SULT2A1 showed moderate expression and were subse-
quently assayed for epigenetic analysis.
Identification of Common Transcription Factors in
Candidate Genes
Genomatix was used to assess common transcription
factor binding sites 500 bp upstream and 100 bp down-
stream of the TSS belonging to nine unique BPA-
associated loci (all UGT1A functional genes are regulated
by a common promoter). Two transcription factor families
were common in at least 97% of the promoters of all rele-
vant transcripts. Both activator protein 1 (AP1) and E-
twenty-six (ETS) related transcription factor binding sites
were identified at least once in the promoter of each locus
as seen on the graphical presentation in Figure 1 (depicted
in purple and green, respectively). The AP1 family consists
of MAF and AP1 related factors such as BACH1/2,
MAFA/B/F/G/K, NRL, NFE2L1/2/3 (NRF1/2/3), and
NRL. The ETS family consists of a variety of transcription
factors containing the Ets DNA binding domain including
ELF1/2/4, ETS1/2, ETV1/4/5, SPI1/B/C, among others.
The consensus sequence for each family and subfamily
along with key transcription factors are listed in Table III.
Interestingly, a majority of transcription factor binding sites
belonging to the ETS family contain cytosine-guanine
(CpG) dinucleotides in the consensus sequence, especially
in the ELF, ELK, and ETV subfamilies.
Methylation Analysis at Candidate Gene Promoters
We studied CpG methylation in and surrounding ETS
transcription factor binding sites at the promoters of three
candidate genes: CES2, COMT, and SULT2A1 (primers in
Table IV). These genes were chosen based on their rela-
tively moderate expression levels across fetal specimens
irrespective of age, sex, and exposure according to RNA-
seq reads. Figure 2 displays the genomic location of the
methylation assays with number of CpG sites, CpG units,
and ETS transcription factor binding sites. Each assay
analyzes multiple CpG units: 4 for CES2 and SULT2A1
and 17 for COMT. Within each assay, we also focused on
specific CpG sites located in the ETS consensus
sequence: CpG site #3 for CES2, and CpG sites #30 &
#31 for COMT. CpG site #1 for SULT2A1 falls within the
Fig. 1. Diagram displaying conserved consensus sequence binding sites
for AP1 (purple) and ETS (green) transcription factor families at the pro-
moters of BPA-associated candidate genes CES2, CES5A, COMT,
GSTA5, SULT2A1, SULT1B1, SULT1C3, SULT6B1, and UGT1A1–10
retrieved from MatInspector. The view includes 500 bp upstream and 100
bp downstream of the transcription start site. Although transcription factor
binding sites were identified for multiple transcripts per gene, only one
promoter transcript is displayed above.
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ETS transcription factor consensus sequences, but was
unresolvable with Sequenom.
The average methylation across all detectable sites in
the COMT assay was not significantly associated with tis-
sue BPA after adjusting for age and sex (P5 0.108);
however, one out of the two CpG sites spanning the puta-
tive ETS consensus sequence showed a significant posi-
tive trend (P5 0.002). An interquartile range (IQR; 10.93
ng/g) increase in total tissue BPA was associated with
0.416% increase in COMT methylation at CpG site #31
(Fig. 2; Table V). Similarly, an IQR (8.28 ng/g) increase
in total tissue BPA was associated with a significant
0.821% increase across all six SULT2A1 CpG sites (Fig.
2; Table V; P5 0.042). The CES2 assay, however, dis-
played decreased site-specific methylation at CpG site #3
and average methylation across all sites with increasing
BPA concentrations, although neither association was sig-
nificant (P5 0.409 and 0.953, respectively).
DISCUSSION
The impact of nutritional and environmental exposures
on the human xenobiotic metabolism system during early
development is not well understood. As previously
described, we quantified total BPA concentrations in 50
1st to 2nd trimester fetal liver specimens, ranging from
below the limit of quantification to 96.8 ng/g total BPA
in tissue [Nahar et al., 2012]. In the current study, we
compared gene expression of over 160 XME genes within
a subset of fetal liver specimens, dichotomized into low
(1.2–2.9 ng/g; n5 4) and high (35.4–56.1 ng/g; n5 4)
total tissue BPA. In total, 14 candidate genes were identi-
fied that exhibit significantly reduced expression in fetal
liver with higher tissue BPA concentrations. With the
exception of the phase I carboxylesterase isoforms, CES2
and CES5A, the majority of BPA-related XME candidate
genes belong to the phase II gene family.
Traditionally, the induction of phase I enzymes follow-
ing drug and xenobiotic exposure is commonly observed,
but our finding of BPA-associated repression of predomi-
nantly phase II XME expression is novel. Only a handful
of studies have previously reported xenobiotic-dependent
repression of primarily phase II metabolizing genes. In a
2008 study examining the ability of endocrine disruptors
to modify estrogen bioavailability in ER-negative HepG2
cells, 80 mM of BPA or 70 mM of genistein exposure was
associated with decreased expression of several phase II
metabolism enzymes, including UGT2B7, UGT2B15, and
SULT1E1 genes [Hanet et al., 2008]. Of our newly identi-
fied exposure-associated XME genes, only the UDP-
glucuronosyltransferases have been previously associated
with BPA as identified from the Comparative Toxicoge-
nomic Database (http://ctdbase.org/). When MCF7 cells
were exposed to 10 nM BPA instead of the control
DMSO vehicle, there was a reduction in UGT1A3 mRNA
expression [Buterin et al., 2006]. In a second study, BPA
was reported to competitively inhibit UGT1A6 and subse-
quently alter metabolism of serotonin in liver microsomes
[Hanioka et al., 2008].
Characterizing XME activity and regulation, especially
throughout fetal development, is challenging given the
difficulty in acquiring relevant human specimens from
sensitive populations. With our unique samples, we were
able to compare relative expression for hundreds of genes
simultaneously using mRNA-next generation sequencing
technology. After compiling all XME related genes, the
TABLE III.Transcription Factors and Consensus Sequences of
Common Transcription Factor Binding Sites (TFBS)
TFBS family Transcription factor
Genomatix
IUPAC sequence
AP1 (AP1 and MAF
related factors)
BACH1 nsaTGAGtcatgny
BACH2 nrTGAGtcann
MAFA TGCWgmnynngcn
MAFB naawntgCTGAcnwarn
MAFK nwaaawTGCTgactn
NFE2 hgCTGAgtcay
NFE2L1 (NRF1) vncGCGCabgcgcvnv
NFE2L2 (NRF2) nmcCGGAagtgac
NRL nncTGCTgasn
ETS (Human and
murine ETS1
factors)
EHF nnacCGGAagtnn
ELF1 nnccGGAAgygnn
ELF2 nnrncaGGAAgnr
ELF3 naanccGGAArtwnn
ELF4 nawmccGGAAgtnn
ELF5 ansmGGAAgtwn
ELK1 nrccGGAArynn
ELK3 nnacCGGAagynn
ELK4 nnacCGGAarynn
ETS1 vsmGGAAgygn
ETS2 dacAGGAaryvnkt
ETV1 nncaGGAAgnn
ETV3 nnacCGGAartnn
ETV4 nnacCGGAwrtnn
ETV5 nnacCGGAwgttn
ETV6 anccGGAAgtann
GABPA nnacCGGAagtnn
GABPB1 nmcCGGAagtgac
SPDEF nnatcCGGAtgynn
SPI1 ngnGGAAstn
SPIB naawgmGGAAgtn
SPIC naaagmGGAAgtwn
The table displays individual transcription factors and their consensus
sequence motifs for each TFBS family. The sequence motifs follow the
standards set by the International Union of Pure and Applied Chemistry
(IUPAC), with highly conserved nucleotides in bold. Upper case letters
(A, C, G, T) show the most frequent nucleotides occurring at greater
than 50% frequency. The degenerate code (R, Y, K, M, S, W) represents
two nucleotides that occur at >75% frequency, but individually contrib-
ute to <50% frequency. All other frequency distributions are represented
by the letter “n”. In particular, several motifs belonging to the ETS fam-
ily contain cytosine-guanine dinucleotides within their highly conserved
sequence.
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top and bottom 25% of normalized RNA-seq reads for
phase I and phase II metabolizing enzymes were reported
for several 1st and 2nd trimester fetal liver tissue in
humans, listed in Table II. Detectable protein levels of
CYP2C9, CYP2C19, CYP3A4, CYP3A5, and CYP3A7
were previously reported in 1st to 2nd trimester human
liver [Hines, 2007]. Specific isoforms for other biotransfor-
mation proteins, such as alcohol dehydrogenase (ADH1A),
epoxide hydrolase (EPHX1, EPHX2), glutathione S-trans-
ferase (GSTA1), and sulfotransferase (SULT1A1) have
also been reported in the early fetal liver [Smith et al.,
1971; Strange et al., 1989; Omiecinski et al., 1994;
Duanmu et al., 2006]. Activities of these phase I and II
enzymes vary between gene families and isoforms with
relative abundance drastically altering over time until adult
levels are reached [Hines and McCarver, 2002; McCarver
and Hines, 2002]. Interestingly, a majority of the BPA
related candidate genes that were identified exhibited rela-
tively low RNA-seq reads as compared with other phase I
and phase II metabolism genes. Thus, the negative associa-
tion between BPA and specific underdeveloped XME
genes may be indicative of repressive effects or delayed
maturation of the candidate XME genes to adult levels,
potentially altering the response to toxicants later in life.
BPA is well known to interact with nuclear receptors
such as estrogen receptor (ERa and b), estrogen related
receptor gamma (ERRy), pregnane X receptor (PXR),
AhR, androgen receptor, and thyroid receptor [Wetherill
et al., 2007; Molina-Molina et al., 2013]. More recently,
studies suggest that endocrine active compounds induce
rapid responses via nongenomic signal transduction path-
ways, and disease susceptibility may depend on the coor-
dination between genomic and nongenomic pathways
[Watson et al., 2011]. In this study, the co-repression of
candidate genes warranted a closer look at common regu-
lators in order to provide insight into novel mechanism of
action for BPA that are relevant to the XME pathway. In
our bioinformatic investigation of regulatory sites, we
identified binding sites for the highly conserved ETS and
AP1 related transcription factors. Extracellular signals
affecting the MAPK and JNK signaling pathways often
converge both upstream and downstream of ETS proteins,
which consist of over 25 family members that can hetero-
dimerize with other transcription factor families, such as
the Fos and Jun domains of AP-1 related proteins [Bassuk
and Leiden, 1995; Yordy and Muise-Helmericks, 2000;
Kyriakis and Avruch, 2001]. Combinatorial control of
specific ETS and AP1 factors, along with other regulators,
is likely to influence transcriptional XME specificity dur-
ing early fetal development, a period in which estriol
(E3) predominates and activates nongenomic processes
[Watson et al., 2011]. While evidence for estrogen recep-
tor independent mechanisms for BPA is increasing, only
a few studies thus far have investigated BPAs influence
on ETS and AP1 factor targets. BPA has been reported toTA
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Fig. 2. Graphic representation of Sequenom Epityper assays with tran-
scription factor binding sites. A. The CES2 assay examines 4 individual
CpG sites located approximately 1,600 to 1,900 bp upstream of the TSS.
The CES2 CpG site #3 is found within an ETS transcription factor-binding
site. B. The COMT assay covers 30 CpGs sites, although due to technical
limitations (e.g. small fragment sizes are not detectable) Sequenom Epi-
Typer outputs only 17 CpG units, spanning approximately 250 bp upstream
and 100 bp downstream of the TSS. An ETS transcription factor-binding
site coincides with CpG sites #30, and #31 on COMT. C. Although CpG
methylation on the ETS consensus sequence of SULT2A1 could not be
directly assessed (CpG site #1), the assay investigates six individual CpG
sites (four CpG units) surrounding the target site, spanning approximately
1,650 to 1,950 bp upstream of the TSS. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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stimulate the PU.1 transcription factor, a relative of the
SP1A, SP1B, and SP1C regulators, in promyelocytic cells
for neutrophilic differentiation [Watanabe et al., 2003]. In
human embryonic kidney cells, BPA at mM doses acti-
vated Nrf1 and Nrf2 transactivation activity and induced
antioxidant response element (ARE) target genes [Chepe-
lev et al., 2013]. Subsequent studies are necessary to
investigate specific ETS and AP1 transcription factors
and their genomic localization using methods such as
chromatin immunoprecipitation coupled with sequencing
(CHIP-seq).
Cis-acting regulation at ETS and AP1 related transcrip-
tion factor binding sites and promoter occupancy, in addi-
tion to post-transcriptional modifications, may alter
environmental response via signal transduction. In particu-
lar, DNA methylation at CpG sites along the consensus
sequence motifs, especially for ETS, can inhibit transcrip-
tion factor binding and transcriptional activity [Hollenhorst
et al., 2011]. In our in silico analysis, ETS proteins were
prevalent in the candidate gene promoters and many of the
ETS consensus sequences contained at least one CpG site.
When Hogart et al. characterized epigenome-wide patterns
across several different primary murine cells, DNA methyla-
tion was highest in hematopoietic stem cells and interest-
ingly, ETS consensus binding motifs were overrepresented
within these methylated regions [Hogart et al., 2012]. Given
that the fetal liver is the major site of hematopoiesis [Timens
and Kamps, 1997], we wanted to examine whether
decreased expression along with increased tissue BPA con-
centrations were associated with increased promoter CpG
methylation at ETS binding sequences. Both site-specific
methylation at the COMT promoter and average CpG meth-
ylation at the SULT2A1 promoter significantly increased
with higher BPA concentrations, although the increase in
DNA methylation was relatively modest. The less than 1%
increase in promoter methylation at the ETS sites of differ-
entially expressed genes suggests that additional regulatory
elements, including other epigenetic mechanisms, influence
expression. For example, the environmentally sensitive
MAPK signaling proteins can associate with chromatin
modifying complexes and directly regulate histone modifi-
cations [Suganuma and Workman, 2012]. Future work will
require further integration of signal transduction pathways
with various epigenetic mechanisms, including histone
modifications and RNA interference, in response to environ-
mental stress at critical windows of development.
Traditionally toxicological studies employed enzymatic
activity assays to understand xenobiotic metabolism in
vitro or in animal models; however, analyzing protein
activity in the developing fetal liver is far more difficult
when access is limited to small amounts of sensitive bio-
banked specimens. With the improvement of real-time
PCR and utilization of next generation sequencing, hun-
dreds of genes can be reliably profiled simultaneously
using small mRNA sample volume and compared with
protein activity. In general, mRNA expression is a good
proxy for protein level, but gene expression does not
always correlate to protein abundance. This discrepancy
can be attributed to differences in the rate of protein or
mRNA synthesis and turn over, or post-transcriptional
regulation [Vogel and Marcotte, 2012]. Hence, examina-
tion of target protein activity and post-transcriptional
modification of regulatory elements in suitable samples
will be necessary in future studies for complete character-
ization of fetal xenobiotic metabolism. Still, in the case
that healthy specimens are available, longitudinal analysis
of the development of human XME pathway is challeng-
ing given the bioethical concerns for fetal tissue, espe-
cially in 3rd trimester. Despite these limitations, gene
expression profiling, even at a narrow window of devel-
opment, can be helpful for exploring early genomic regu-
lation that occur with a changing environment.
While the task of investigating BPAs influence on XMEs
may be clearer in animal models in which investigators
TABLE V.Mixed Effects and Linear Regression Models Comparing Average and Individual CpG (Within ETS binding sites)
Methylation With BPA Exposure, Adjusted for Gestational Age and Sex
Methylation assay N
Change in % methylation
for an IQR change in tissue
total BPA (ng/g) P
CES2
Average (4 total CpG; 4 CpG units)a 50 20.008 0.953
CpG #3b 50 20.114 0.409
COMT
Average (30 total CpG; 17 CpG units)a 50 0.080 0.108
CpG #30b 50 20.010 0.851
CpG #31b 50 0.416 0.002
SULT2A1
Average (6 total CpG; 4 CpG units)a 40 0.821 0.042
Interquartile Range (IQR)5 10.93 ng/g for CES2 and COMT, and 8.28 ng/g for SULT2A1.
aMixed-effects model to account for multiple adjacent CpG sites, adjusted for gestation age and sex.
bLinear regression at biologically relevant CpG sites, adjusted for gestational age and sex.
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exercise control over experimental design and model choice,
here we utilize human fetal liver samples from an NIH-
funded biobank. These samples are derived from individuals
who may have been exposed to a wide array of compounds
and maternal factors. Thus, a variety of unmeasured but
related factors, such as co-exposure to other endocrine
active compounds, may confound our results.
In the presence of endogenous hormones and growth fac-
tors, phase I and phase II metabolizing gene expression and
enzyme function matures until adult baseline levels are
attained, either after birth, during childhood, or in adoles-
cence. Therefore, exposure to environmental compounds,
especially during early life when the capacity for xenobi-
otic metabolism is suboptimal, may increase susceptibility
to disease in the developing fetus and children [Allegaert
et al., 2008]. When XME gene expression was compared in
fetal liver exposed in utero to physiologically low and high
BPA concentrations, subtle decreases in specific phase I
and II metabolizing genes were observed. Although BPA
may not immediately dysregulate essential proteins or
directly cause disease, the endocrine active compound may
stunt XME maturation via signaling pathways and epige-
netic mechanisms. Considering the daily and cumulative
exposure to a myriad of compounds in humans, the inabil-
ity to adequately respond to these insults suggests potential
consequences for health later in life.
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